These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7875155)

  • 1. Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer.
    Smith HO; Goldberg GL; Carol L; Davidson SA; Tomaino C; Centrilla L; Runowicz CD
    Eur J Gynaecol Oncol; 1994; 15(6):411-7. PubMed ID: 7875155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor.
    Rusthoven J; Levin L; Eisenhauer E; Mazurka J; Carmichael J; O'Connell G; Bryson P; Hirte H; Koski B
    J Natl Cancer Inst; 1991 Dec; 83(23):1748-53. PubMed ID: 1770554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study.
    Edmonson JH; Suman VJ; Dalton RJ; Bro WC; Gallenberg MM; Long HJ; Levitt R; Hatfield AK; Krook JE; Mailliard JA; Gerstner JB;
    Cancer Invest; 2001; 19(6):597-602. PubMed ID: 11486702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses.
    Fennelly D; Schneider J; Spriggs D; Bengala C; Hakes T; Reich L; Barakat R; Curtin J; Moore MA; Hoskins W
    J Clin Oncol; 1995 May; 13(5):1160-6. PubMed ID: 7537799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
    Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
    Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study.
    Schilder RJ; Brady MF; Spriggs D; Shea T
    Gynecol Oncol; 2003 Jan; 88(1):3-8. PubMed ID: 12504619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
    Fujiwara K; Sakuragi N; Suzuki S; Yoshida N; Maehata K; Nishiya M; Koshida T; Sawai H; Aotani E; Kohno I
    Gynecol Oncol; 2003 Sep; 90(3):637-43. PubMed ID: 13678738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study.
    Toner GC; Green M; Bishop JF; McKendrick J; Cebon J; Sheridan WP; Lockbaum P; O'Byrne J; Fox RM
    Am J Clin Oncol; 1998 Jun; 21(3):263-9. PubMed ID: 9626795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
    Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
    Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer.
    Trask C; Silverstone A; Ash CM; Earl H; Irwin C; Bakker A; Tobias JS; Souhami RL
    J Clin Oncol; 1991 Jul; 9(7):1131-7. PubMed ID: 2045855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of carboplatin and cyclophosphamide combination chemotherapy for the treatment of advanced ovarian cancer.
    Teeling M; Carney DN
    Eur J Gynaecol Oncol; 1990; 11(3):219-24. PubMed ID: 2209642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer.
    Wandt H; Birkmann J; Denzel T; Schäfer K; Schwab G; Pilz D; Egger H; Both A; Gallmeier WM
    Bone Marrow Transplant; 1999 Apr; 23(8):763-70. PubMed ID: 10231137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.
    Kaye SB; Lewis CR; Paul J; Duncan ID; Gordon HK; Kitchener HC; Cruickshank DJ; Atkinson RJ; Soukop M; Rankin EM
    Lancet; 1992 Aug; 340(8815):329-33. PubMed ID: 1353804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma.
    Martoni A; Panetta A; Angelelli B; Melotti B; Pannuti F
    J Chemother; 1993 Feb; 5(1):47-51. PubMed ID: 8459265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
    Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
    Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.